Online citations, reference lists, and bibliographies.
← Back to Search

Effusion Cytology Of Malignant Mesothelioma Enables Earlier Diagnosis And Recognizes Patients With Better Prognosis.

Sulaf Abd Own, Jonas Höijer, Gunnar Hillerdahl, K. Dobra, A. Hjerpe
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
A conclusive diagnosis of malignant mesothelioma (MM) can be based on effusion cytology using the guidelines for the cytopathologic diagnosis of epithelioid and mixed-type MM. Briefly, the diagnosis is obtained when the mesothelial phenotype of malignant cells is established by ancillary techniques. This study is based on the comparison of the overall survival rates of patients with MM when diagnosed by effusion cytology, histopathology, or a combination of both. A total of 144 patients were diagnosed with epithelioid and mixed-type pleural MM at Karolinska University Hospital between 2004 and 2013. The diagnosis was obtained by histopathology in 74 cases and by cytological examination of pleural effusion in 70 cases. In 29 of the latter cases, a diagnostic biopsy was obtained simultaneously. A total of 104 patients received chemotherapy. All diagnoses were supported by clinical findings, including computer tomography scans. The median time between first symptoms and diagnosis was similar for cytology and histopathology. However, a delay of more than 6 months after first symptoms was seen in many patients in the histopathology group, resulting in late onset of treatment. The overall survival and proportion of long-term survival were significantly better for cases diagnosed by cytology. Similarly, a better survival, following a cytological diagnosis, was also seen in patients who were only provided the best supportive care. Accurate cytological diagnosis enables conclusive diagnosis of MM. Our finding enables the initiation of treatment as soon as the cytological diagnosis is established, avoiding further delay and deterioration of patient survival and possibilities for treatment.
This paper references
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
Abstract 319: Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance
D. Sahay (2016)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
A. De Rienzo (2016)
Life Expectancy in Pleural and Peritoneal Mesothelioma
R. Shavelle (2017)
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma
A. Hjerpe (2015)
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
Carmen Flores-Staino (2010)
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.
E. Taioli (2017)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma
Sanjeevan Muruganandan (2017)
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
A. Segal (2013)
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis
A. Reid (2014)
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
B. Granger (2005)
Management of malignant pleural mesothelioma – part 3
T. Klikovits (2016)
Survival from malignant mesothelioma: where are we now?
Ann Marshall (2015)
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.
T. Allen (2005)
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
A. Hjerpe (2018)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases
F. Galateau-Sallé (2004)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak (2018)
Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up
G. Berry (2012)
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry
Xue-ying Su (2011)
Pleural well-differentiated papillary mesothelioma: a case report.
S. Kao (2009)

Semantic Scholar Logo Some data provided by SemanticScholar